NASDAQ OMX

Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari

Dela

Pressmeddelande

22 januari 2018

Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari

Immunicum AB (IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att Immunicums ledning kommer att presentera bolaget och delta under flera kommande branschkonferenser och forskningskonferenser under januari och februari.

ASCO/SITC - Clinical Immuno-Oncology Symposium
Datum: 25-27 januari 2018
Plats: San Francisco Marriott Marquis, San Francisco, Kalifornien, USA

Aktiedagen Lund
Datum: 30 januari 2018
Presentation: tisdag den 30 januari, 10:15 CET
Plats: Medicon Village, Hörsalen Scheelevägen 2, Lund
För att delta, registrera dig här https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-30-januari

Cholangiocarcinoma Foundation Annual Conference
Datum: 31 januari-2 februari 2018
Presentation: Poster Session: torsdag den 1 februari, kl. 19:00-21:00 Mountain Standard Time
Plats: Salt Lake Marriott Downtown at City Creek, Salt Lake City, Utah, USA

Biotech and Money World Congress
Datum: 5-6 februari 2018
Presentation: måndag den 5 februari, kl. 16.30 Greenwich Mean Time - Sal: Private Dining
Plats: etc. venues, 200 Aldersgate, St. Pauls, London, Storbritannien

4th Annual Immuno-Oncology 360°
Datum: 7-9 februari 2018
Plats: The Roosevelt Hotel, New York City, New York, USA

BIO CEO & Investor Conference
Datum: 12-13 februari 2018
Presentation: måndag den 12 februari, kl. 14:00 Eastern Standard Time - Odets Room, 4th Floor
Plats: New York Marriott Marquis, New York City, New York, USA

För ytterligare information kontakta:

Carlos de Sousa, VD, Immunicum
Telefon: +46 (0) 31 41 50 52
E-post: info@immunicum.com

Investor Relations, Sverige

Helena Stångberg
Hallvarsson & Halvarsson
Telefon: +46 709 71 12 53
E-post: ir@immunicum.com 

Mediakontakt

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telefon: +49 172 861 8540
E-post: ir@immunicum.com 

Om Immunicum AB (publ)

Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet. Företagets ledande produkt, ilixadencel, bestående av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundstomme i modern kombinationsbehandling av ett flertal olika solida tumörformer. Immunicum är grundat och baserat i Sverige och är noterat på Nasdaq Stockholm. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Virgin Pulse and RedBrick Health Joining Forces to Create World's Largest Digital Employee Wellbeing and Engagement Company21.5.2018 17:00Pressmeddelande

Merger Will Create First and Only One-Stop-Shop for Employee Health, Wellbeing and Benefits Engagement; Combined Company Will Have More Than 3,300 Customers Across 190 Countries PROVIDENCE, R.I., May 21, 2018 (GLOBE NEWSWIRE) -- Providence-based Virgin Pulse and Minneapolis-based RedBrick Health announced today that the industry pioneers will merge, creating the world's largest, most comprehensive digital health and engagement company. This powerful combination will deliver the industry's only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle - from screening and assessment to activation, behavior change and the adoption of sustainable, healthy habits. "We are thrilled to join with RedBrick to set a new vision and standard for employee health, wellbeing and engagement," said David Osborne, Virgin Pulse CEO, who will serve as CEO of the combined company. "Bringing

Hotels.com App Wins 2018 MediaPost Appy Award in Travel & Tourism Category21.5.2018 16:00Pressmeddelande

Developed by EPAM, app is recognized for creativity and excellence in app design NEWTOWN, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Hotels.com® and EPAM Systems, Inc. (NYSE:EPAM) announced their triumphant win at the 2018 MediaPost Appy Awards in the Travel and Tourism category this week. The Hotels.com mobile app, developed in collaboration with EPAM Systems, Inc., a leading global provider of digital platform engineering and software development services, has been crowned the best app developed for airlines, hotels, travel search engines, destinations, cruises, travel advice or car rentals. With over 70 million downloads and a 4.5+ star rating from consumers on both iOS and Android app stores, the Hotels.com app has now been recognized by the industry leading Appy Awards, which honor creativity and excellence in app design. The app provides a simple, fast and secure way for users to plan, book and manage hotel reservations, and allows travelers to book hundreds of thousands of places to

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Claroty Launches Channel Program and Announces New Industrial Cybersecurity Partnerships21.5.2018 15:00Pressmeddelande

Claroty Vision Program Expands Global Reach and Joint Solution Delivery with OT Leaders, Including Dimension Data/NTT Security, Optiv, and Kudelski Security NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network security, today unveiled Claroty Vision, a new global channel partner program for integrated solution partners, managed service providers (MSPs), and resellers. The program is tailored to provide partners with the tools and resources they need to accelerate revenue in the fast-growing industrial cybersecurity market. The company also announced several new partnerships under the Claroty Vision banner, including the addition of Optiv and Kudelski Security. Comprised of four participation levels - Elite, Premier, Authorized, and Referral - the Claroty Vision program provides partners with a broad range of tools, benefits, and incentives such as increased margin, deal registration, an online demo environment, and co-marketing activitie

Wabtec and GE Transportation to Merge, Creating Global Leader for Rail Equipment, Services and Software21.5.2018 13:00Pressmeddelande

Strategic Combination Will Drive Shareholder Value Creation by Accelerating Innovation in Transportation and Logistics Following the transaction, Wabtec will have approximately $8 billion in revenues, a more diversified business mix, higher margins, and approximately 15 percent cash EPS accretion in year one. Both businesses are expected to benefit from the cyclical tailwinds they are experiencing as industry conditions improve. Complementary businesses and large global installed base will create additional opportunities for cross-selling, aftermarket services growth and new solutions in a rapidly evolving industry. GE Transportation is positioned for a substantial rebound, with estimated adjusted EBITDA growing from about $750 million in 2018 to between $900 million and $1 billion in 2019. Substantial annual run-rate synergies of $250 million and a net present value of approximately $1.1 billion of net tax benefit will accrue to the combined company. The transaction is valued at appro

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum